•
DN
DNTH
Dianthus Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
2.06B
Volume
734.89K
52W High
$48.09
52W Low
$13.37
Open
$0.00
Prev Close
$46.60
Day Range
0.00 - 0.00
About Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Latest News
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight
GlobeNewswire Inc.•Jan 14
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
The Motley Fool•Jan 7
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.•Jan 5
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
GlobeNewswire Inc.•Oct 29
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
GlobeNewswire Inc.•Oct 16
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
GlobeNewswire Inc.•Sep 10
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
GlobeNewswire Inc.•Sep 8
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
GlobeNewswire Inc.•Sep 7